Publications by authors named "Geoffrey Kim"

Claim this Profile
D
Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer.
Yujia Xia, Jie Zhou, Xiaolei Xun, Luke Johnston, Ting Wei, Geoffrey Kim

NPJ Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy.
Yujia Xia, Jie Zhou, Xiaolei Xun, Jin Zhang, Ting Wei, Geoffrey Kim

Insights Imaging· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Landscape of cancer clinical trials in India - a comprehensive analysis of the Clinical Trial Registry-India.
Peng Gao, Justin Chen, Zhongyu Hong, Marcus Choi, Allison Morgan, Geoffrey Kim

Lancet Reg Health Southeast Asia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remote Monitoring and Data Collection for Decentralized Clinical Trials.
Bobby Daly, Otis W Brawley, Mary K Gospodarowicz, Olufunmilayo I Olopade, Lola Fashoyin-Aje, Geoffrey Kim

JAMA Netw Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decoding kinase-adverse event associations for small molecule kinase inhibitors.
Xiajing Gong, Meng Hu, Jinzhong Liu, Geoffrey Kim, James Xu

Nat Commun· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition.
Bob T Li, Bobby Daly, Mary Gospodarowicz, Monica M Bertagnolli, Otis W Brawley, Geoffrey Kim

Nat Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.
Boris Shulgin, Yuri Kosinsky, Andrey Omelchenko, Lulu Chu, Ganesh Mugundu, Geoffrey Kim

Oncoimmunology· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
Yan Ji, Jin Y Jin, David M Hyman, Geoffrey Kim, Ajit Suri

Clin Transl Sci· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
Suparna B Wedam, Julia A Beaver, Laleh Amiri-Kordestani, Erik Bloomquist, Shenghui Tang, Geoffrey Kim

J Clin Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious Mutation-Associated Advanced Ovarian Cancer.
Sanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, Laura L Fernandes, Shenghui Tang, Kim J Robertson, Geoffrey Kim

Clin Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
Thomas J Herzog, Gwynn Ison, Ronald D Alvarez, Sanjeeve Balasubramaniam, Deborah K Armstrong, Geoffrey Kim

Gynecol Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
Chana Weinstock, Sean Khozin, Daniel Suzman, Lijun Zhang, Shenghui Tang, Geoffrey Kim

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Setting the Record Straight on FDA Approvals in Oncology.
Gideon Blumenthal, Geoffrey Kim, Richard Pazdur

JAMA Intern Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory considerations on endpoints in ovarian cancer drug development.
Sanjeeve Balasubramaniam, Geoffrey S Kim, Amy E McKee, Richard Pazdur

Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Yang-Min Ning, Daniel Suzman, V Ellen Maher, Lijun Zhang, Shenghui Tang, Geoffrey Kim

Oncologist· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enrollment of older adults on oncology trials: An FDA perspective.
Harpreet Singh, Julia A Beaver, Geoffrey Kim, Richard Pazdur

J Geriatr Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory watch: From big data to smart data: FDA's INFORMED initiative.
Sean Khozin, Geoffrey Kim, Richard Pazdur

Nat Rev Drug Discov· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective.
Amanda J Walker, Hyun Kim, Haleh Saber, Paul G Kluetz, Geoffrey Kim

Int J Radiat Oncol Biol Phys· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
Julia A Beaver, Abraham Tzou, Gideon M Blumenthal, Amy E McKee, Geoffrey Kim

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis.
James Xunhai Xu, V Ellen Maher, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Geoffrey Kim

Oncologist· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
Harpreet Singh, Michael Brave, Julia A Beaver, Joyce Cheng, Shenghui Tang, Geoffrey Kim

Clin Cancer Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials-Response.
Paul G Kluetz, Elektra J Papadopoulos, Laura Lee Johnson, Martha Donoghue, Virginia E Kwitkowski, Geoffrey Kim

Clin Cancer Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Amanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, Erik Bloomquist, Shengui Tang, Geoffrey Kim

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.
Sean Khozin, Meredith Chuk, Tamy Kim, Geoffrey Kim, Richard Pazdur

Nat Rev Drug Discov· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.
Calvin Chen Sheng, Laleh Amiri-Kordestani, Todd Palmby, Thomas Force, Charles C Hong, Geoffrey Kim

JACC Basic Transl Sci· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis